# A Study to Evaluate LTI-03 in Newly Diagnosed Idiopathic Pulmonary Fibrosis (IPF) Patients

> **NCT05954988** · PHASE1 · COMPLETED · sponsor: **Rein Therapeutics** · enrollment: 24 (actual)

## Conditions studied

- Idiopathic Pulmonary Fibrosis

## Interventions

- **DRUG:** LTI-03
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT05954988
- **Lead sponsor:** Rein Therapeutics
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2023-07-06
- **Primary completion:** 2024-09-25
- **Final completion:** 2024-09-25
- **Target enrollment:** 24 (ACTUAL)
- **Last updated:** 2025-07-31


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05954988

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05954988, "A Study to Evaluate LTI-03 in Newly Diagnosed Idiopathic Pulmonary Fibrosis (IPF) Patients". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT05954988. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*